Chronic Myelogenous Leukemia
Newly discovered Bcr-abl kinase inhibitor may have therapeutic potential in CML
Published in Cancer Weekly, February 14th, 2006
Nathanael Gray, of the Genomics Institute of the Novartis Foundation, and colleagues reported their finding in the February 2006 issue of Nature Chemical Biology.
CML is a common form of leukemia that is typically characterized by two genes, BCR and ABL1, connecting when they should be separate. The resulting fusion protein causes cellular signaling pathways to be on when they should be off and contributes to the development of CML.
CML patients are developing resistance to the current clinical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-02-14)
More Articles from Cancer Weekly
- Bone Tumors
FDG-PET used to detect bone tumors when bone scintigraphy gave negative findings - Breast Cancer
New breast magnetic resonance imaging technique endorsed - Colon Cancer
Use of artepillin C helps prevent colon cancer - Drug Resistance
Chromosomal alterations resulted in drug resistance in cancer cells - Prostate Cancer
Antiprostasome antibody titer used as supplemental prostate cancer marker - Abdominal Tumors
Abdominal position shifts detected with radiation-planning CT scans - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
